Skip to main content
Clinical Trials/NCT04183530
NCT04183530
Recruiting
Not Applicable

The Individualized Accurate Diagnosis and Treatment, as Well as the Prevention of Acute Exacerbation of Chronic Objective Pulmonary Disease(COPD) Based on Multidimensional Data

Wuhan Union Hospital, China1 site in 1 country1,000 target enrollmentOctober 16, 2019

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Copd
Sponsor
Wuhan Union Hospital, China
Enrollment
1000
Locations
1
Primary Endpoint
The metabolomics analysis of participates' urine or stool
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. Hence, the investigators' research integrated multi-dimensional data of COPD patients, which may provide an invaluable bioinformatic resource for understanding the underlying molecular alterations that drive disease progression, with the goal of developing individualized accurate diagnostic and therapeutic inventions.

Detailed Description

Chronic obstructive pulmonary disease (COPD) is known as progressive lung disease and the fourth leading cause of death worldwide. Acute exacerbations of COPD (AECOPD) is an important event of disease progression worsening in airway function and respiratory symptoms, bringing about respiratory failure, and increasing the rates of mortality. Despite valuable efforts, there is still no Individualized accurate diagnostic and prognostic tool for COPD. In this context, the investigators are to perform comprehensive transcriptomic, proteomic, metabonomic and exosome characterization of COPD patients and healthy controls. Biological samples of COPD participants, including blood, urine, stool, saliva, bronchoalveolar lavage fluid and clinical characteristics are going to be collected from the remaining materials of the routine clinical examination. And samples of healthy controls will be collected from the rest of the healthy examination practice. By integrating the multi-dimensional data, the investigators aim to elucidate the impact of molecular alterations driving phenotypic variation and to delineate the mechanisms of AECOPD for prospective exploration of personalized, precision-based clinical care.

Registry
clinicaltrials.gov
Start Date
October 16, 2019
End Date
December 30, 2024
Last Updated
4 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Wuhan Union Hospital, China
Responsible Party
Principal Investigator
Principal Investigator

Yang Jin

Professor

Wuhan Union Hospital, China

Eligibility Criteria

Inclusion Criteria

  • Patient has signed informed consent.
  • Patients diagnosed with COPD or fully healthy participants.

Exclusion Criteria

  • Tumor disease.
  • Heart disease.
  • Thyroid disease.

Outcomes

Primary Outcomes

The metabolomics analysis of participates' urine or stool

Time Frame: through study completion, an average of 1 year

Predominately include metabolic target analysis, metabolic profiling analysis

The transcriptome analysis of participates' serum or plasma

Time Frame: through study completion, an average of 1 year

Include the transcriptome data of serum,plasma or exosomes inside

The proteomics analysis of bronchoalveolar lavage fluid and saliva

Time Frame: through study completion, an average of 1 year

Differentially expressed proteins between SCOPD and AECOPD which associated with disease progression were analyesd

Study Sites (1)

Loading locations...

Similar Trials